Literature DB >> 21098644

Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.

Shinji Yamazaki1, Judith Skaptason, David Romero, Sylvia Vekich, Hannah M Jones, Weiwei Tan, Keith D Wilner, Tatiana Koudriakova.   

Abstract

The objective of this study was to assess the physiologically based pharmacokinetic (PBPK) model for predicting plasma concentration-time profiles of orally available cMet kinase inhibitors, (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine (PF02341066) and 2-[4-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol (PF04217903), in humans. The prediction accuracy of pharmacokinetics (PK) by PBPK modeling was compared with that of a traditional one-compartment PK model based on allometric scaling. The predicted clearance values from allometric scaling with the correction for the interspecies differences in protein binding were used as a representative comparison, which showed more accurate PK prediction in humans than the other methods. Overall PBPK modeling provided better prediction of the area under the plasma concentration-time curves for both PF02341066 (1.2-fold error) and PF04217903 (1.3-fold error) compared with the one-compartment PK model (1.8- and 1.9-fold errors, respectively). Of more importance, the simulated plasma concentration-time profiles of PF02341066 and PF04217903 by PBPK modeling seemed to be consistent with the observed profiles showing multiexponential declines, resulting in more accurate prediction of the apparent half-lives (t(1/2)): the observed and predicted t(1/2) values were, respectively, 10 and 12 h for PF02341066 and 6.6 and 6.3 h for PF04217903. The predicted t(1/2) values by the one-compartment PK model were 17 h for PF02341066 and 1.9 h for PF04217903. Therefore, PBPK modeling has the potential to be more useful and reliable for the PK prediction of PF02341066 and PF04217903 in humans than the traditional one-compartment PK model. In summary, the present study has shown examples to indicate that the PBPK model can be used to predict PK profiles in humans.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21098644     DOI: 10.1124/dmd.110.035857

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  13 in total

Review 1.  Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.

Authors:  Hannah M Jones; Kapil Mayawala; Patrick Poulin
Journal:  AAPS J       Date:  2012-12-27       Impact factor: 4.009

Review 2.  Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies.

Authors:  Dane R Liston; Myrtle Davis
Journal:  Clin Cancer Res       Date:  2017-03-31       Impact factor: 12.531

3.  Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.

Authors:  Shinji Yamazaki
Journal:  AAPS J       Date:  2012-12-19       Impact factor: 4.009

4.  Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model.

Authors:  Zhi-wei Gao; Yun-ting Zhu; Ming-ming Yu; Bin Zan; Jia Liu; Yi-fan Zhang; Xiao-yan Chen; Xue-ning Li; Da-fang Zhong
Journal:  Acta Pharmacol Sin       Date:  2015-11-23       Impact factor: 6.150

5.  Novel in vitro dynamic metabolic system for predicting the human pharmacokinetics of tolbutamide.

Authors:  Cai-Fu Xue; Zhe Zhang; Yan Jin; Bin Zhu; Jun-Fen Xing; Guo Ma; Xiao-Qiang Xiang; Wei-Min Cai
Journal:  Acta Pharmacol Sin       Date:  2018-04-12       Impact factor: 6.150

6.  Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.

Authors:  Guo-fu Li; Kun Wang; Rui Chen; Hao-ru Zhao; Jin Yang; Qing-shan Zheng
Journal:  Acta Pharmacol Sin       Date:  2012-10-22       Impact factor: 6.150

7.  Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin.

Authors:  Min-Ho Park; Seok-Ho Shin; Jin-Ju Byeon; Gwan-Ho Lee; Byung-Yong Yu; Young G Shin
Journal:  Korean J Physiol Pharmacol       Date:  2016-12-21       Impact factor: 2.016

8.  Crizotinib Inhibits Hyperpolarization-activated Cyclic Nucleotide-Gated Channel 4 Activity.

Authors:  Zhushan Zhang; Tai-Qin Huang; Igor Nepliouev; Hengtao Zhang; Adam S Barnett; Paul B Rosenberg; Sai-Hong I Ou; Jonathan A Stiber
Journal:  Cardiooncology       Date:  2017-01-19

9.  Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model.

Authors:  Caifu Xue; Xunjie Zhang; Weimin Cai
Journal:  Pharmaceutics       Date:  2017-12-21       Impact factor: 6.321

10.  Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development.

Authors:  Hm Jones; K Rowland-Yeo
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.